Continuous Flow Left Ventricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart Failure Patients

Joseph G. Rogers, Keith D. Aaronson, Andrew J. Boyle, Stuart D. Russell, Carmelo A. Milano, Francis D. Pagani, Brooks S. Edwards, Soon Park, Ranjit John, John V. Conte, David J. Farrar, Mark S. Slaughter

Research output: Contribution to journalArticle

Abstract

Objectives: This study sought to assess the impact of continuous flow left ventricular assist devices (LVADs) on functional capacity and heart failure-related quality of life. Background: Newer continuous-flow LVAD are smaller and quieter than pulsatile-flow LVADs. Methods: Data from advanced heart failure patients enrolled in the HeartMate II LVAD (Thoratec Corporation, Pleasanton, California) bridge to transplantation (BTT) (n = 281) and destination therapy (DT) (n = 374) trials were analyzed. Functional status (New York Heart Association [NYHA] functional class, 6-min walk distance, patient activity scores), and quality of life (Minnesota Living With Heart Failure [MLWHF] and Kansas City Cardiomyopathy Questionnaires [KCCQ]) were collected before and after LVAD implantation. Results: Compared with baseline, LVAD patients demonstrated early and sustained improvements in functional status and quality of life. Most patients had NYHA functional class IV symptoms at baseline. Following implant, 82% (BTT) and 80% (DT) of patients at 6 months and 79% (DT) at 24 months improved to NYHA functional class I or II. Mean 6-min walk distance in DT patients was 204 m in patients able to ambulate at baseline, which improved to 350 and 360 m at 6 and 24 months. There were also significant and sustained improvements from baseline in both BTT and DT patients in median MLWHF scores (by 40 and 42 U in DT patients, or 52% and 55%, at 6 and 24 months, respectively), and KCCQ overall summary scores (by 39 and 41 U, or 170% and 178%). Conclusions: Use of a continuous flow LVAD in advanced heart failure patients results in clinically relevant improvements in functional capacity and heart failure-related quality of life.

Original languageEnglish (US)
Pages (from-to)1826-1834
Number of pages9
JournalJournal of the American College of Cardiology
Volume55
Issue number17
DOIs
StatePublished - Apr 27 2010

Fingerprint

Heart-Assist Devices
Heart Failure
Quality of Life
Transplantation
Cardiomyopathies
Therapeutics
Pulsatile Flow

Keywords

  • continuous flow
  • functional status
  • HeartMate II
  • quality of life
  • ventricular assist devices

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Continuous Flow Left Ventricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart Failure Patients. / Rogers, Joseph G.; Aaronson, Keith D.; Boyle, Andrew J.; Russell, Stuart D.; Milano, Carmelo A.; Pagani, Francis D.; Edwards, Brooks S.; Park, Soon; John, Ranjit; Conte, John V.; Farrar, David J.; Slaughter, Mark S.

In: Journal of the American College of Cardiology, Vol. 55, No. 17, 27.04.2010, p. 1826-1834.

Research output: Contribution to journalArticle

Rogers, JG, Aaronson, KD, Boyle, AJ, Russell, SD, Milano, CA, Pagani, FD, Edwards, BS, Park, S, John, R, Conte, JV, Farrar, DJ & Slaughter, MS 2010, 'Continuous Flow Left Ventricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart Failure Patients', Journal of the American College of Cardiology, vol. 55, no. 17, pp. 1826-1834. https://doi.org/10.1016/j.jacc.2009.12.052
Rogers, Joseph G. ; Aaronson, Keith D. ; Boyle, Andrew J. ; Russell, Stuart D. ; Milano, Carmelo A. ; Pagani, Francis D. ; Edwards, Brooks S. ; Park, Soon ; John, Ranjit ; Conte, John V. ; Farrar, David J. ; Slaughter, Mark S. / Continuous Flow Left Ventricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart Failure Patients. In: Journal of the American College of Cardiology. 2010 ; Vol. 55, No. 17. pp. 1826-1834.
@article{099938d4ca134c15b588d9a2ed537b82,
title = "Continuous Flow Left Ventricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart Failure Patients",
abstract = "Objectives: This study sought to assess the impact of continuous flow left ventricular assist devices (LVADs) on functional capacity and heart failure-related quality of life. Background: Newer continuous-flow LVAD are smaller and quieter than pulsatile-flow LVADs. Methods: Data from advanced heart failure patients enrolled in the HeartMate II LVAD (Thoratec Corporation, Pleasanton, California) bridge to transplantation (BTT) (n = 281) and destination therapy (DT) (n = 374) trials were analyzed. Functional status (New York Heart Association [NYHA] functional class, 6-min walk distance, patient activity scores), and quality of life (Minnesota Living With Heart Failure [MLWHF] and Kansas City Cardiomyopathy Questionnaires [KCCQ]) were collected before and after LVAD implantation. Results: Compared with baseline, LVAD patients demonstrated early and sustained improvements in functional status and quality of life. Most patients had NYHA functional class IV symptoms at baseline. Following implant, 82{\%} (BTT) and 80{\%} (DT) of patients at 6 months and 79{\%} (DT) at 24 months improved to NYHA functional class I or II. Mean 6-min walk distance in DT patients was 204 m in patients able to ambulate at baseline, which improved to 350 and 360 m at 6 and 24 months. There were also significant and sustained improvements from baseline in both BTT and DT patients in median MLWHF scores (by 40 and 42 U in DT patients, or 52{\%} and 55{\%}, at 6 and 24 months, respectively), and KCCQ overall summary scores (by 39 and 41 U, or 170{\%} and 178{\%}). Conclusions: Use of a continuous flow LVAD in advanced heart failure patients results in clinically relevant improvements in functional capacity and heart failure-related quality of life.",
keywords = "continuous flow, functional status, HeartMate II, quality of life, ventricular assist devices",
author = "Rogers, {Joseph G.} and Aaronson, {Keith D.} and Boyle, {Andrew J.} and Russell, {Stuart D.} and Milano, {Carmelo A.} and Pagani, {Francis D.} and Edwards, {Brooks S.} and Soon Park and Ranjit John and Conte, {John V.} and Farrar, {David J.} and Slaughter, {Mark S.}",
year = "2010",
month = "4",
day = "27",
doi = "10.1016/j.jacc.2009.12.052",
language = "English (US)",
volume = "55",
pages = "1826--1834",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "17",

}

TY - JOUR

T1 - Continuous Flow Left Ventricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart Failure Patients

AU - Rogers, Joseph G.

AU - Aaronson, Keith D.

AU - Boyle, Andrew J.

AU - Russell, Stuart D.

AU - Milano, Carmelo A.

AU - Pagani, Francis D.

AU - Edwards, Brooks S.

AU - Park, Soon

AU - John, Ranjit

AU - Conte, John V.

AU - Farrar, David J.

AU - Slaughter, Mark S.

PY - 2010/4/27

Y1 - 2010/4/27

N2 - Objectives: This study sought to assess the impact of continuous flow left ventricular assist devices (LVADs) on functional capacity and heart failure-related quality of life. Background: Newer continuous-flow LVAD are smaller and quieter than pulsatile-flow LVADs. Methods: Data from advanced heart failure patients enrolled in the HeartMate II LVAD (Thoratec Corporation, Pleasanton, California) bridge to transplantation (BTT) (n = 281) and destination therapy (DT) (n = 374) trials were analyzed. Functional status (New York Heart Association [NYHA] functional class, 6-min walk distance, patient activity scores), and quality of life (Minnesota Living With Heart Failure [MLWHF] and Kansas City Cardiomyopathy Questionnaires [KCCQ]) were collected before and after LVAD implantation. Results: Compared with baseline, LVAD patients demonstrated early and sustained improvements in functional status and quality of life. Most patients had NYHA functional class IV symptoms at baseline. Following implant, 82% (BTT) and 80% (DT) of patients at 6 months and 79% (DT) at 24 months improved to NYHA functional class I or II. Mean 6-min walk distance in DT patients was 204 m in patients able to ambulate at baseline, which improved to 350 and 360 m at 6 and 24 months. There were also significant and sustained improvements from baseline in both BTT and DT patients in median MLWHF scores (by 40 and 42 U in DT patients, or 52% and 55%, at 6 and 24 months, respectively), and KCCQ overall summary scores (by 39 and 41 U, or 170% and 178%). Conclusions: Use of a continuous flow LVAD in advanced heart failure patients results in clinically relevant improvements in functional capacity and heart failure-related quality of life.

AB - Objectives: This study sought to assess the impact of continuous flow left ventricular assist devices (LVADs) on functional capacity and heart failure-related quality of life. Background: Newer continuous-flow LVAD are smaller and quieter than pulsatile-flow LVADs. Methods: Data from advanced heart failure patients enrolled in the HeartMate II LVAD (Thoratec Corporation, Pleasanton, California) bridge to transplantation (BTT) (n = 281) and destination therapy (DT) (n = 374) trials were analyzed. Functional status (New York Heart Association [NYHA] functional class, 6-min walk distance, patient activity scores), and quality of life (Minnesota Living With Heart Failure [MLWHF] and Kansas City Cardiomyopathy Questionnaires [KCCQ]) were collected before and after LVAD implantation. Results: Compared with baseline, LVAD patients demonstrated early and sustained improvements in functional status and quality of life. Most patients had NYHA functional class IV symptoms at baseline. Following implant, 82% (BTT) and 80% (DT) of patients at 6 months and 79% (DT) at 24 months improved to NYHA functional class I or II. Mean 6-min walk distance in DT patients was 204 m in patients able to ambulate at baseline, which improved to 350 and 360 m at 6 and 24 months. There were also significant and sustained improvements from baseline in both BTT and DT patients in median MLWHF scores (by 40 and 42 U in DT patients, or 52% and 55%, at 6 and 24 months, respectively), and KCCQ overall summary scores (by 39 and 41 U, or 170% and 178%). Conclusions: Use of a continuous flow LVAD in advanced heart failure patients results in clinically relevant improvements in functional capacity and heart failure-related quality of life.

KW - continuous flow

KW - functional status

KW - HeartMate II

KW - quality of life

KW - ventricular assist devices

UR - http://www.scopus.com/inward/record.url?scp=77950897411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950897411&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2009.12.052

DO - 10.1016/j.jacc.2009.12.052

M3 - Article

C2 - 20413033

AN - SCOPUS:77950897411

VL - 55

SP - 1826

EP - 1834

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 17

ER -